AKT1 and B-cell chronic lymphocytic leukemia: As described above, O-GlcNAcylation potentiates the tumor suppressive activity of wild-type p53 (80, 81) and down-regulates AKT and NFκB activity in non-proliferating CLL cells (2) (Figure 2).